Pharmacological Values of Medicinal Mushrooms for Prostate Cancer Therapy: The Case of Ganoderma Lucidum

Prostate cancer (PCa) is the most common male malignancy in many Western countries. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops to hormone-refractory tumors due to the accumulation of mutations in the androgen receptor and/or the acquisition o...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition and cancer 2009-01, Vol.61 (1), p.16-26
Main Authors: Mahajna, Jamal, Dotan, Nesly, Zaidman, Ben-Zion, Petrova, Roumyana D, Wasser, Solomon P
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
apoptosis
Apoptosis - drug effects
Biological and medical sciences
cell proliferation
drug therapy
Feeding. Feeding behavior
Fundamental and applied biological sciences. Psychology
Ganoderma lucidum
Gene Expression Regulation, Neoplastic - drug effects
Gynecology. Andrology. Obstetrics
Humans
literature reviews
Male
Male genital diseases
Medical sciences
medicinal properties
men
Neoplasms, Hormone-Dependent - drug therapy
Neoplasms, Hormone-Dependent - metabolism
Nephrology. Urinary tract diseases
prostatic neoplasms
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - metabolism
Receptors, Androgen - metabolism
Reishi - chemistry
Signal Transduction
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer (PCa) is the most common male malignancy in many Western countries. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops to hormone-refractory tumors due to the accumulation of mutations in the androgen receptor and/or the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of prostate cancer. To date, no effective therapy is available for clinically hormone-insensitive or hormone-refractory stages of prostate cancer.
ISSN:0163-5581
1532-7914
DOI:10.1080/01635580802379323